Drug Formulary Review Archives – March 1, 2004
March 1, 2004
View Issues
-
New guidelines announced for preventing heart disease in women
The American Heart Association (AHA) in Dallas has released new guidelines for preventing heart disease and stroke in women that are tailored to each individuals cardiac event risk. -
Cost-effectiveness analysis gives global view of price
While on rotation as a drug information specialty resident, one pharmacist decided to take a more comprehensive look at how much one drug would cost the health center if it were added to the formulary. -
Pilot program offers one-on-one consultations
By calling an 800 number and paying a $5 fee, residents in four Wyoming cities can have face-to-face consultations with clinical pharmacists, who not only review the residents health and medication history but make cost-saving suggestions as well. -
Journal Review: Memantine shows benefit for moderate-to-severe AD
Memantine (Namenda) helped lessen the symptoms of patients with moderate-to-severe Alzheimers disease (AD) who were already receiving treatment with donepezil (Aricept), according to a study published in the Jan. 21 issue of the Journal of the American Medical Association. -
News Briefs
New hepatotoxicity warning added to nevirapine (Viramune); FDA announces improved drug approval results in 2003; Savings noted with increased use of beta-blockers; First TB vaccine trial in 60 years to begin; Study: Consumers dont understand drug formularies; Vantin antibiotic batch recalled. -
In the Pipeline
The following drugs are in various stages of clinical studies and trials. -
Drug Criteria & Outcomes: Palonosetron (Aloxi) Formulary Evaluation
Palonosetron, developed by MGI Pharma and its partner Helsinn Healthcare SA, is a recently approved selective antagonist of serotonin subtype 3 receptors (5-HT3). -
Drug Criteria & Outcomes: New FDA Approvals
These drugs recently received final approval from the U.S. Food and Drug Administration (FDA).